The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Ofev (nintedanib) for the treatment of progressive fibrosing interstitial lung diseases (ILDs). This positive opinion follows Ofev’s approval for that same…
Low blood levels of haptoglobin-related protein (HRP), a protein with antioxidant properties, may serve as a biomarker of idiopathic pulmonary fibrosis (IPF), according to a recent study. The data also highlighted that IPF patients show significant changes in the levels of proteins involved in inflammatory and immune responses, as…
Stem cells derived from the placental amniotic membrane — one of the membranes of the amniotic sac that surrounds a baby while it is still in the womb — have the ability to slow the progression of lung tissue scarring in a mouse model of idiopathic pulmonary fibrosis (IPF),…
While the ongoing COVID-19 pandemic won’t have much of an impact on cash available for new biotech startups, it has begun to cause delays in the development of gene therapies to treat a variety of rare diseases. That’s the consensus of industry experts who spoke in a May 26 webinar…
A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF). The study “A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study” was published…
Ofev (nintedanib), an oral medication by Boehringer Ingelheim, is now approved to treat people with progressive fibrosing interstitial lung diseases (ILDs) in the U.S. and Canada. These approvals, by the U.S. Food and Drug Administration (FDA) and Health Canada, come on the heels of findings from the…
European authorities must step up efforts to screen babies for a multitude of genetic disorders, a panel of experts suggested during a May 14-15 online medical conference. The session was part of the 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) — which was to have occurred…
Ofev, an approved treatment of idiopathic pulmonary fibrosis (IPF), may be considered as a monotherapy for patients who also have non‐small cell lung cancer and are unable to tolerate cancer chemotherapy, a case study reported. …
Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) — which was set for May 14–15 in…
The U.S. Food and Drug Administration (FDA) has designated AMP945, Amplia Therapeutics’ investigational anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF), an orphan drug, supporting its development, the company announced. Its decision came about one month after AMP945 also received orphan drug status as a potential pancreatic cancer…
Get regular updates to your inbox.
